Deal Flow - Pharmaceutical Executive


Deal Flow

Actavis Going Private?

July 3, 2007

The month in deals: Merck KGaA's generics unit goes to Mylan; Genzyme acquires its partner in a key oncology drug; and Amgen makes significant acquisitions in kidney disease and diabetes/inflammatory diseases

Driven to License

February 1, 2007

Goodbye, M&As. Hello, L&As. The new trend in business development is licensing deals and acquisitions. The hot categories are CNS, oncology, and immunology. Now let's get bizzy.

Finance: Good Alternatives

September 1, 2006

The extra cash validated for equity investors that Acorda could go out and market Zanaflex.

Slow Deal Flow?

September 1, 2006

Roche, Johnson & Johnson, and Teva have demonstrated formidable deal making for many years. But generally, business development capabilities in the pharma industry remain very patchy, with the number of poor performers far out-weighing the good.


Click here